Clarithromycin/clofazimine/rifabutin companion diagnostic - RedHill Biopharma/Quest Diagnostics

Drug Profile

Clarithromycin/clofazimine/rifabutin companion diagnostic - RedHill Biopharma/Quest Diagnostics

Alternative Names: RHB 104 companion diagnostic

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RedHill Biopharma
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Crohn's disease
  • Phase II Multiple sclerosis

Most Recent Events

  • 05 Sep 2017 Phase-III development is ongoing in USA, Canada, New Zealand, Australia, Bulgaria, Czech Republic, Poland, Serbia, Slovakia and Israel (NCT01951326)
  • 06 Oct 2016 RedHill Biopharma collaborates with Baylor College of Medicine to develop companion diagnostic for the fixed dose combination of clarithromycin/clofazimine/rifabutin
  • 03 Jun 2015 RedHill Biopharma receives a notice of patent allowance for clarithromycin/clofazimine/rifabutin companion diagnostic in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top